These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 25341922)

  • 1. Insulin activates EGFR by stimulating its interaction with IGF-1R in low-EGFR-expressing TNBC cells.
    Shin M; Yang EG; Song HK; Jeon H
    BMB Rep; 2015 Jun; 48(6):342-7. PubMed ID: 25341922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Partial agonistic effect of cetuximab on epidermal growth factor receptor and Src kinase activation in triple‑negative breast cancer cell lines.
    Gurdal H; Tuglu MM; Bostanabad SY; Dalkiliç B
    Int J Oncol; 2019 Apr; 54(4):1345-1356. PubMed ID: 30720056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
    Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
    Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade.
    Martin JL; de Silva HC; Lin MZ; Scott CD; Baxter RC
    Mol Cancer Ther; 2014 Feb; 13(2):316-28. PubMed ID: 24337110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a Resistance Mechanism to IGF-IR Targeting in Human Triple Negative MDA-MB-231 Breast Cancer Cells.
    Tsui J; Qi S; Perrino S; Leibovitch M; Brodt P
    Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33916323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene.
    Roberts MS; Anstine LJ; Finke VS; Bryson BL; Webb BM; Weber-Bonk KL; Seachrist DD; Majmudar PR; Keri RA
    Breast Cancer Res; 2020 Jun; 22(1):66. PubMed ID: 32552913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-inhibition of epidermal growth factor receptor and insulin-like growth factor receptor 1 enhances radiosensitivity in human breast cancer cells.
    Li P; Veldwijk MR; Zhang Q; Li ZB; Xu WC; Fu S
    BMC Cancer; 2013 Jun; 13():297. PubMed ID: 23777562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-Targeting IGF-1R and Autophagy Enhances the Effects of Cell Growth Suppression and Apoptosis Induced by the IGF-1R Inhibitor NVP-AEW541 in Triple-Negative Breast Cancer Cells.
    Wu W; Ma J; Shao N; Shi Y; Liu R; Li W; Lin Y; Wang S
    PLoS One; 2017; 12(1):e0169229. PubMed ID: 28046018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
    Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
    Schanzer JM; Wartha K; Croasdale R; Moser S; Künkele KP; Ries C; Scheuer W; Duerr H; Pompiati S; Pollman J; Stracke J; Lau W; Ries S; Brinkmann U; Klein C; Umana P
    J Biol Chem; 2014 Jul; 289(27):18693-706. PubMed ID: 24841203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IGF-1/IGF-1R/FAK/YAP Transduction Signaling Prompts Growth Effects in Triple-Negative Breast Cancer (TNBC) Cells.
    Rigiracciolo DC; Nohata N; Lappano R; Cirillo F; Talia M; Scordamaglia D; Gutkind JS; Maggiolini M
    Cells; 2020 Apr; 9(4):. PubMed ID: 32325700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Visualising dual downregulation of insulin-like growth factor receptor-1 and vascular endothelial growth factor-A by heat shock protein 90 inhibition effect in triple negative breast cancer.
    Terwisscha van Scheltinga AG; Berghuis P; Nienhuis HH; Timmer-Bosscha H; Pot L; Gaykema SB; Lub-de Hooge MN; Kosterink JG; de Vries EG; Schröder CP
    Eur J Cancer; 2014 Sep; 50(14):2508-16. PubMed ID: 25027745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit.
    Raju U; Molkentine DP; Valdecanas DR; Deorukhkar A; Mason KA; Buchholz TA; Meyn RE; Ang KK; Skinner H
    Cancer Med; 2015 Jan; 4(1):65-74. PubMed ID: 25355701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast cancer.
    Madden JM; Mueller KL; Bollig-Fischer A; Stemmer P; Mattingly RR; Boerner JL
    Breast Cancer Res Treat; 2014 Sep; 147(2):283-93. PubMed ID: 25129346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells.
    Merrouche Y; Fabre J; Cure H; Garbar C; Fuselier C; Bastid J; Antonicelli F; Al-Daccak R; Bensussan A; Giustiniani J
    Oncotarget; 2016 Aug; 7(33):53350-53361. PubMed ID: 27462789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Role for ER-Beta in the Effects of Low-Density Lipoprotein Cholesterol and 27-Hydroxycholesterol on Breast Cancer Progression: Involvement of the IGF Signalling Pathway?
    Mashat RM; Zielinska HA; Holly JMP; Perks CM
    Cells; 2021 Dec; 11(1):. PubMed ID: 35011656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy.
    van der Veeken J; Oliveira S; Schiffelers RM; Storm G; van Bergen En Henegouwen PM; Roovers RC
    Curr Cancer Drug Targets; 2009 Sep; 9(6):748-60. PubMed ID: 19754359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth hormone-releasing hormone induced transactivation of epidermal growth factor receptor in human triple-negative breast cancer cells.
    Vacas E; Muñoz-Moreno L; Valenzuela PL; Prieto JC; Schally AV; Carmena MJ; Bajo AM
    Peptides; 2016 Dec; 86():153-161. PubMed ID: 27816751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
    Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
    Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual treatments targeting IGF-1R, PI3K, mTORC or MEK synergize to inhibit cell growth, induce apoptosis, and arrest cell cycle at G1 phase in MDA-MB-231 cell line.
    Ayub A; Yip WK; Seow HF
    Biomed Pharmacother; 2015 Oct; 75():40-50. PubMed ID: 26463630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.